Invention:
This invention is a rapid image-based drug screening software platform for bioactive compounds that can block SARS-CoV-2 replication cycles. The invention utilizes a custom image processing algorithm that utilizes microscopy images to develop drug response profiles to identify lead compounds. This technology can also be used to neutralize antibodies, monobodies, or peptides.
Background:
Within the drug discovery process, lead compounds are chemical compounds that show desired biological or pharmacological activity and may initiate the development of a new clinically relevant compound. Lead compounds are commonly used as a starting point in drug design. With the advancement of technology, computer-aided drug design (CADD) has been incorporated into lead compound discovery within the drug discovery process.
Since the severe acute respiratory syndrome SARS-CoV-2 (Coronavirus) has spread globally, there is a greater need to look for novel vaccines and drugs that alleviate and prevent contracting the virus. This includes identifying a possible lead bioactive compound that will block the coronavirus replication cycle to assist in the prevention and contamination of this current global pandemic.
Applications:
- 3D cell based analysis
- Image-based screening for bioactive compounds for blocking SARS-CoV-2
- Can be used to neutralize antibodies, monobodies, or peptides
Advantages:
- Rapid
- High dimensional characterization
- Predictable
- Complex
- Accurate
